Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019032626) METHODS OF TREATMENT
Latest bibliographic data on file with the International BureauSubmit observation

Pub. No.: WO/2019/032626 International Application No.: PCT/US2018/045683
Publication Date: 14.02.2019 International Filing Date: 07.08.2018
IPC:
A61K 31/195 (2006.01) ,A61P 9/08 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
185
Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19
Carboxylic acids, e.g. valproic acid
195
having an amino group
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9
Drugs for disorders of the cardiovascular system
08
Vasodilators for multiple indications
Applicants:
ARENA PHARMACEUTICALS, INC. [US/US]; 6154 Nancy Ridge Drive San Diego, California 92121, US
Inventors:
ADAMS, John W.; US
ANDERSON, Christen M.; US
SHANAHAN, William R.; US
Agent:
ZUNIC, Valentin B.; US
Priority Data:
62/541,95607.08.2017US
62/711,36927.07.2018US
Title (EN) METHODS OF TREATMENT
(FR) PROCÉDÉS DE TRAITEMENT
Abstract:
(EN) Provided in some embodiments are methods of treating or preventing Raynaud's, comprising prescribing and/or administering to an individual in need thereof 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(FR) Selon certains modes de réalisation, l'invention concerne des procédés de traitement ou de prévention la maladie de Raynaud, comprenant la prescription et/ou l'administration à un individu qui en a besoin de l'acide 2- (( (1r,4r)-4-(( (4-chlorophényl)) (phényl) carbamoyloxy) méthyl) cyclohexyl) méthoxy) acétique (composé 1), ou un sel, hydrate ou solvate pharmaceutiquement acceptable de celui-ci.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)